Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer

M. H. Cohen; P. B. Chretien; D. C. Ihde; B. E. Fossieck; R. Makuch; P. A. Bunn; A. V. Johnston; S. E. Shackney; M. J. Matthews; S. D. Lipson; D. E. Kenady; J. D. Minna

doi:10.1001/jama.241.17.1813

Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer

M. H. Cohen, P. B. Chretien, D. C. Ihde, B. E. Fossieck, R. Makuch, P. A. Bunn, A. V. Johnston, S. E. Shackney, M. J. Matthews, S. D. Lipson, D. E. Kenady, J. D. Minna

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with small-cell bronchogenic carcinoma who received intensive remission-induction chemotherapy randomly received either thymosin fraction V, 60 mg/sq m or 20 mg/sq m twice weekly, or no thymosin treatment during the initial six weeks of chemotherapy. Chemotherapy was then continued for two years. Thymosin administration did not increase the complete response rate. Patients receiving thymosin, 60 mg/sq m, had significantly prolonged survival times relative to the other treatment groups. This benefit was due to prolonged relapse-free survival in complete responders to treatment. The mechanism by which thymosin increased survival duration is unclear but may relate to restoration of immune deficits due to disease or treatment.

Original language	English (US)
Pages (from-to)	1813-1815
Number of pages	3
Journal	Journal of the American Medical Association
Volume	241
Issue number	17
DOIs	https://doi.org/10.1001/jama.241.17.1813
State	Published - 1979

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.241.17.1813

Cite this

Cohen, M. H., Chretien, P. B., Ihde, D. C., Fossieck, B. E., Makuch, R., Bunn, P. A., Johnston, A. V., Shackney, S. E., Matthews, M. J., Lipson, S. D., Kenady, D. E., & Minna, J. D. (1979). Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. Journal of the American Medical Association, 241(17), 1813-1815. https://doi.org/10.1001/jama.241.17.1813

Cohen, MH, Chretien, PB, Ihde, DC, Fossieck, BE, Makuch, R, Bunn, PA, Johnston, AV, Shackney, SE, Matthews, MJ, Lipson, SD, Kenady, DE & Minna, JD 1979, 'Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer', Journal of the American Medical Association, vol. 241, no. 17, pp. 1813-1815. https://doi.org/10.1001/jama.241.17.1813

@article{ff4cf5c6371f4f109a6ed0a36dba92d6,

title = "Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer",

abstract = "Patients with small-cell bronchogenic carcinoma who received intensive remission-induction chemotherapy randomly received either thymosin fraction V, 60 mg/sq m or 20 mg/sq m twice weekly, or no thymosin treatment during the initial six weeks of chemotherapy. Chemotherapy was then continued for two years. Thymosin administration did not increase the complete response rate. Patients receiving thymosin, 60 mg/sq m, had significantly prolonged survival times relative to the other treatment groups. This benefit was due to prolonged relapse-free survival in complete responders to treatment. The mechanism by which thymosin increased survival duration is unclear but may relate to restoration of immune deficits due to disease or treatment.",

author = "Cohen, {M. H.} and Chretien, {P. B.} and Ihde, {D. C.} and Fossieck, {B. E.} and R. Makuch and Bunn, {P. A.} and Johnston, {A. V.} and Shackney, {S. E.} and Matthews, {M. J.} and Lipson, {S. D.} and Kenady, {D. E.} and Minna, {J. D.}",

year = "1979",

doi = "10.1001/jama.241.17.1813",

language = "English (US)",

volume = "241",

pages = "1813--1815",

journal = "Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "17",

}

TY - JOUR

T1 - Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer

AU - Cohen, M. H.

AU - Chretien, P. B.

AU - Ihde, D. C.

AU - Fossieck, B. E.

AU - Makuch, R.

AU - Bunn, P. A.

AU - Johnston, A. V.

AU - Shackney, S. E.

AU - Matthews, M. J.

AU - Lipson, S. D.

AU - Kenady, D. E.

AU - Minna, J. D.

PY - 1979

Y1 - 1979

N2 - Patients with small-cell bronchogenic carcinoma who received intensive remission-induction chemotherapy randomly received either thymosin fraction V, 60 mg/sq m or 20 mg/sq m twice weekly, or no thymosin treatment during the initial six weeks of chemotherapy. Chemotherapy was then continued for two years. Thymosin administration did not increase the complete response rate. Patients receiving thymosin, 60 mg/sq m, had significantly prolonged survival times relative to the other treatment groups. This benefit was due to prolonged relapse-free survival in complete responders to treatment. The mechanism by which thymosin increased survival duration is unclear but may relate to restoration of immune deficits due to disease or treatment.

AB - Patients with small-cell bronchogenic carcinoma who received intensive remission-induction chemotherapy randomly received either thymosin fraction V, 60 mg/sq m or 20 mg/sq m twice weekly, or no thymosin treatment during the initial six weeks of chemotherapy. Chemotherapy was then continued for two years. Thymosin administration did not increase the complete response rate. Patients receiving thymosin, 60 mg/sq m, had significantly prolonged survival times relative to the other treatment groups. This benefit was due to prolonged relapse-free survival in complete responders to treatment. The mechanism by which thymosin increased survival duration is unclear but may relate to restoration of immune deficits due to disease or treatment.

UR - http://www.scopus.com/inward/record.url?scp=0018746826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018746826&partnerID=8YFLogxK

U2 - 10.1001/jama.241.17.1813

DO - 10.1001/jama.241.17.1813

M3 - Article

C2 - 219267

SN - 0098-7484

VL - 241

SP - 1813

EP - 1815

JO - Journal of the American Medical Association

JF - Journal of the American Medical Association

IS - 17

ER -

Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this